Pulmonary Fungal Pathogen Multiplex PCR Panel

  • Test Code

    1000

  • CPT Code

    87801 x1

  • Clinical Significance

    Multiplex PCR allows for the simultaneous detection of multiple fungal pathogens from a single sample. This is especially valuable in patients presenting with non-specific respiratory symptoms or community-acquired pneumonia, where fungal infections may mimic bacterial or viral causes. These fungi (Histoplasma, Blastomyces, Coccidiodes, and Pneumocystis) are common causes of opportunistic infections, particularly in HIV-positive or immunocompromised individuals. Early and accurate identification can significantly improve patient outcomes, and in addition, patients may have co-infections with more than one fungal pathogen and multiplex PCR can identify these cases, allowing for more comprehensive treatment planning.

  • Methodology

    Qualitative Real-Time PCR (Polymerase Chain Reaction)

  • Limitations

    403 MVista® Histoplasma DNA, PCR: When tested in cultures of 10 8 – 10 9 organisms/mL, cross-reactions occurred with Paracoccidioides brasiliensis, Aspergillus flavus, Aspergillus nidulans, and Aspergillus niger.

    404 MVista® Blastomyces DNA, PCR: When tested in cultures of 10 8 – 10 9 organisms/mL, cross-reactions occurred with Cryptococcus neoformans.

    405 MVista® Coccidioides DNA, PCR: No cross-reactions or interfering substances were identified during validation.

    402 MVista® Pneumocystis DNA, PCR: No cross-reactions or interfering substances were identified during validation.

  • Specimen Collection

    Bronchoalveolar lavage (BAL) fluid to a sterile, leakproof container. Tracheal aspirate and bronchial wash will be reported with a rare specimen comment.

  • Minimum Specimen Requirements

    BAL/Trachial Aspirate*/Bronchial Wash*: 0.5 mL

    * Reported with rare specimen comment applied.

  • Specimen Stability
    • Room Temperature/Ambient: 30 days
    • Refrigerated: 30 days
    • Frozen: 30 days
  • Specimen Rejection
    • CSF, sputum, and all other non-respiratory samples.
    • Two unique patient identifiers are required on the specimen container.
    • Specimens with particulate matter or viscosity that would not allow the specimen to be pipetted will be rejected.
  • Shipping

    Samples may be shipped on dry ice or frozen ice packs.

  • Turnaround Time

    BAL/Trachial Aspirate/Bronchial Wash: Same Day

  • Reference Range

    Not detected

  • Interpretative Information

    PCR testing should be done in conjunction with appropriate antigen or antibody testing. A positive PCR result indicates the DNA was detected in the sample and that organism could be the cause of disease. Some organisms (molds and yeasts) can be commensals (or colonizers) and found in non-sterile locations such as the respiratory, GI, and urinary systems – without causing disease. A negative result indicates DNA was not detected in the sample but does not rule-out that organism as the cause of disease. All results should be interpreted considering the full clinical picture.

  • Additional Information

    This test was developed, and its analytical performance characteristics were determined by MiraVista Diagnostics. It has not been cleared or approved by the FDA; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

  • Panel Components

* New positives may require confirmation.

** Turnaround times are provided as ranges, and may vary depending on daily testing volumes and specimen type.

*** Test set-up: Samples received by 10:30 AM are eligible for same-day testing. Same-day testing is not guaranteed and may vary based on daily test volume, sample receipt time, testing schedules, and sample type. Some samples may require pretreatment and/or confirmatory testing, which can extend turnaround time (TAT).

**** Two unique patient identifiers are required on specimen containers. 

***** Specimens with particulate matter or viscosity that would not allow the specimen to be pipetted will be rejected.

CONTACT US

Only Available at MiraVista Diagnostics: MycoMEIA® Aspergillus Galf Urine EIA
MiraVista Diagnostics now offers MycoMEIA® Aspergillus Galf Urine EIA, a urine-based antigen assay that complements serum galactomannan (GM) testing and may improve diagnostic confidence for invasive aspergillosis (IA).

Close Welcome Bar